06/09/2026
As part of Alzheimer’s & Brain Awareness Month, Cognivue is highlighting past research exploring more efficient and accessible approaches to Alzheimer’s disease screening pathways.
At AAIC 2025, Cognivue presented a poster on a “2-stage screening” approach designed to help identify individuals with cognitive impairment and a high likelihood of amyloid positivity using Cognivue Clarity and the Cognivue Amyloid Risk Measure (CARM). The proposed model paired cognitive assessment with follow-up blood biomarker testing as a staged approach intended to help determine which individuals may warrant additional amyloid evaluation.[1]
Building on this concept, Cognivue and Lucent Diagnostics collaborated on a CTAD 2025 poster evaluating whether a 2-stage screening strategy using Cognivue Clarity and LucentAD Complete could help stratify individuals more efficiently while reducing the need for confirmatory amyloid PET imaging. The analysis utilized Bio-Hermes study participants who completed Cognivue Clarity, LucentAD Complete, and amyloid PET imaging as the reference standard.[2]
The CTAD 2025 findings showed that the 2-stage approach using Cognivue Clarity and LucentAD Complete classified 85% of participants into clinically meaningful groups, while only 15% of the sample required confirmatory amyloid PET imaging.
As Alzheimer’s prevention and treatment trials continue to expand, this past research into scalable and cost-effective screening strategies may help improve identification of individuals appropriate for further evaluation, clinical trial enrollment, or additional follow-up.
Cognivue will have more research updates at the upcoming Alzheimer's Association International Conference (AAIC) taking place on July 12-16, 2026, so be on the lookout for future posts.
References:
[1] Galvin JE, et al. Two-Stage Screening for Alzheimer’s Disease Clinical Trial Recruitment Enrichment. Poster presented at AAIC 2025.
[2] Galvin JE, et al. Combining Cognivue Clarity and LucentAD Complete for Time- and Cost-Efficient Two-Stage Screening for Alzheimer’s Disease. Poster presented at CTAD 2025.
